Effect of Physical Activity on Cardiorespiratory Fitness and Markers of Cardiovascular Disease Risk During Menopause: A Systematic Review and Meta-Analysis of Randomised-Controlled Trials
Amie Woodward , Amanda J. Mason-Jones , Matthew Faires , Victoria Jones , Alexander Beaumont
Journal of Science in Sport and Exercise ›› : 1 -23.
Effect of Physical Activity on Cardiorespiratory Fitness and Markers of Cardiovascular Disease Risk During Menopause: A Systematic Review and Meta-Analysis of Randomised-Controlled Trials
The menopause transition is associated with increased cardiovascular disease (CVD) risk. Cardiorespiratory fitness (CRF) is inversely associated with CVD risk in healthy populations. CRF thus represents a responsive target for physical activity (PA) interventions in menopausal populations. The aims were: (1) to investigate the impact of PA interventions on CRF and CVD risk factors, respectively, in perimenopausal and menopausal women, and (2) to examine the association between changes in CRF and CVD risk factors following PA interventions.
Five databases (PubMed, EMBASE, Web of Science, CENTRAL, SPORTDiscus) were searched from inception to December 2023 for randomised controlled trials of PA interventions in menopausal females with non-active controls. The primary outcome was CRF, presented as VO2max. The Cochrane Risk of Bias Tool was used to assess bias. Heterogeneity was observed using I2. Effect measures were presented as Mean Difference (MD) with 95% Confidence Interval (CI). Meta-regression was conducted to examine the relationship between changes in VO2max and reduction in CVD risk.
Seventy-eight studies with 5332 participants were included in meta-analysis. For VO2max, there was a favourable effect of exercise versus control (3.51 mL/kg/min, 95% CI 2.75 to 4.27, 1968 participants, 30 trials). Considerable heterogeneity was observed. Meta-regression indicated a small, significant inverse association between changes in VO2max and changes in systolic blood pressure in sensitivity analysis.
All types of PA improved CRF. Moreover, improvements in CRF through PA intervention may be associated with concomitant reductions in systolic blood pressure, which is a major risk for CVD. Many outcomes had unexplained heterogeneity and unclear risk of bias due to lack of transparent reporting. Future research should investigate age and PA intensity as moderator variables. Future RCTs should focus on transparent reporting.
Menopause / Physical activity / Cardiovascular disease / Meta-analysis
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
Association AH. The facts about women and heart disease 2020. https://www.goredforwomen.org/en/about-heart-disease-in-women/facts. Accessed 27 Feb 2023. |
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
Borenstein M, Hedges L, Higgins J. Comprehensive meta-analysis. Version 4. Englewood, NJ: Biostat, Inc.; 2022. |
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
Cochrane. RevMan. Version: 8.6.0. 2024. https://revman.cochrane.org/info. Accessed 17 Nov 2024. |
| [27] |
Cochrane Work . The Cochrane highly sensitive search strategies for identifying randomized trials in PubMed: the Cochrane Collaboration. 2008. https://work.cochrane.org/pubmed. Accessed 25 Nov 2023. |
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
Deeks J, Higgins J, Altman DG, McKenzie J, Veroniki AA . Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins J, Thomas J, Chandler J, editors. Cochrane handbook for systematic reviews of interventions. Version 6.4. 2023. https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-10. Accessed 17 Nov 2024. |
| [34] |
Department of Health and Social Care. Women’s health strategy for England. 2022. https://www.gov.uk/government/publications/womens-health-strategy-for-england/womens-health-strategy-for-england. Accessed 17 Mar 2023. |
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
Higgins J, Eldridge S, Li T. Chapter 23: Including variants on randomized trials . In: Higgins J, T homas J, Chandler J, editors. Cochrane handbook for systematic reviews of interventions. Version 6.5. 2023. https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-23. Accessed 17 Nov 2024. |
| [58] |
Higgins J, Li T, Deeks Je. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins J, Thomas J, Chandler J, editors. Cochrane handbook for systematic reviews of interventions. Version 6.5. https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-06. Accessed 23 Feb 2024. |
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
National Institute for Health and Care Excellence. Diagnosis of menopause and perimenopause. 2022. Accessed 22 Apr 2024. |
| [98] |
NHS. Physical activity guidelines for adults aged 19 to 64. 2021. https://www.nhs.uk/. Accessed 18 Apr 2024. |
| [99] |
NICE. Menopause: diagnosis and management, 2019, London, National Institute for Health and Care Excellence (NICE) |
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
|
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
|
| [140] |
|
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia: Covidence; 2024. |
| [145] |
WHO. Guidelines on physical activity and sedentary behaviour, 2020, Geneva, World Health Organization |
| [146] |
|
| [147] |
|
| [148] |
|
| [149] |
|
| [150] |
|
The Author(s)
/
| 〈 |
|
〉 |